Ovid Therapeutics (OVID) Profit After Tax (2016 - 2026)
Ovid Therapeutics' (OVID) quarterly Profit After Tax came in at -$17.0 million in Q1 2026, down 66.55% YoY from -$50.8 million in Q1 2025, and down 275.55% on a QoQ basis from $9.7 million in Q4 2025.
Ovid Therapeutics (OVID) Profit After Tax (2016 - 2026) Analysis & Trends
Ovid Therapeutics (OVID) has 11 years of Profit After Tax data on file, last reported at -$17.0 million in Q1 2026.
- Quarterly Profit After Tax fell 66.55% year-over-year to -$17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.2 million (up 2.98% YoY) and the FY2025 annual result came in at -$17.4 million, up 34.17% from the prior year.
- Profit After Tax declined to -$17.0 million in Q1 2026, from $9.7 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $9.7 million in Q4 2025 to a low of -$17.0 million in Q1 2026.
- A 5-year average of -$9.8 million and a median of -$12.0 million in 2022 frame the typical range for Profit After Tax.
- The widest YoY moves for Profit After Tax: up 204.58% in 2025, down 154.97% in 2025.
- Tracing OVID's Profit After Tax over 5 years: stood at -$11.5 million in 2022, then sank by 33.18% to -$15.3 million in 2023, then soared by 39.61% to -$9.3 million in 2024, then soared by 204.58% to $9.7 million in 2025, then plunged by 275.55% to -$17.0 million in 2026.
- The last three Profit After Tax figures came in at -$17.0 million (Q1 2026), $9.7 million (Q4 2025), and -$12.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | -16.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.99 Mn |
| Dec 31, 2025 | 9.68 Mn |
| Sep 30, 2025 | -12.20 Mn |
| Jun 30, 2025 | -4.68 Mn |
| Mar 31, 2025 | -10.20 Mn |
| Dec 31, 2024 | -9.25 Mn |
| Sep 30, 2024 | -14.01 Mn |
| Jun 30, 2024 | 8.52 Mn |
| Mar 31, 2024 | -11.69 Mn |
| Dec 31, 2023 | -15.32 Mn |
| Sep 30, 2023 | -11.25 Mn |
| Jun 30, 2023 | -12.41 Mn |
| Mar 31, 2023 | -13.36 Mn |
| Dec 31, 2022 | -11.50 Mn |
| Sep 30, 2022 | -11.97 Mn |
| Jun 30, 2022 | -14.59 Mn |
| Mar 31, 2022 | -16.11 Mn |
| Dec 31, 2021 | -26.00 Mn |
| Sep 30, 2021 | -11.38 Mn |
| Jun 30, 2021 | -15.79 Mn |